Toxin exposure and immune factors in B-cell non-Hodgkin lymphoma
Official title: Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma Across the Military Healthcare System
Run by Henry M. Jackson Foundation for the Advancement of Military Medicine · NCT07652580 · Data updated 2026-11-12
This study tests how toxin exposure, genetics, and immune issues relate to B-cell non-Hodgkin lymphoma in active-duty service members and other Military Health System beneficiaries.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 4 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Henry M. Jackson Foundation for the Advancement of Military Medicine Academic / other |
| Locations | 3 sites (Bethesda, Maryland and 2 other locations) |
| Status | Recruiting |
| Started | May 1, 2025 |
| Main results expected | May 1, 2028 |
| Study ends | May 1, 2028 |
| Registry record updated | September 3, 2026 |
| Trial ID | NCT07652580 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children aged 4 years and older and adults with a clinical diagnosis of B-cell NHL who are willing to provide biospecimens and undergo whole genome sequencing.
✕Probably not a fit
Patients who do not have B-cell NHL or who cannot undergo required procedures or sequencing may not benefit directly.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective observational registry and biorepository studying the links between occupational and environmental toxin exposures, immune dysregulation, and germline genetics in individuals with B-cell NHL. Participants provide exposure histories, medical information, and biospecimens for immune and genomic testing, with up to 3 years of follow-up. Data are collected from clinical records, surveys, and the DoD ILER, and may include blood, skin fibroblasts, tumor tissue, bone marrow, and archived samples. Analyses will include germline and somatic sequencing to explore associations with NHL subtype, immune function, treatment outcomes, and survival. Enrollment includes adults and pediatric patients across three cohorts based on disease status and age.
Why it matters
Potential benefit: Findings could improve understanding of risk factors and enable more personalized monitoring and care for people at risk of or living with B-cell NHL.
How similar studies have gone: While similar registries have advanced knowledge in toxin exposure and lymphoma, this study's military-active population and comprehensive biospecimen collection are relatively unique.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 4 years old and older with a clinical diagnosis of B-cell NHL. * Must be willing to undergo phlebotomy and/or skin punch biopsy. * Must be willing to undergo whole genome sequencing, which includes return of primary and secondary findings. Exclusion Criteria: * Has any condition that, in the opinion of the Principal Investigator, contraindicates participation in this study. Examples of situation that may contraindicate participation include but are not limited to a) some cases of cerebral vascular accidents where an individual no longer has the capacity to make their own medical decisions and a conservator or responsible family member is not available and b) an individual has active suicidal ideation and is a danger to themselves at the time of enrollment. * Does not have access to health care and primary care clinician. * Actively undergoing induction treatment for NHL.
Where it's running
-
Walter Reed National Military Medical Center
Bethesda, Maryland, United States Recruiting -
Uniformed Services University of the Health Sciences
Bethesda, Maryland, United States Active not recruiting -
Naval Medical Center Portsmouth
Portsmouth, Virginia, United States Active not recruiting
Study contacts
- Principal investigator: Christin Destefano — Uniformed Services University of the Health Sciences
- Study coordinator: Christin B. Destefano, MD, Lt Col, MC, USAF
- Email: christin.destefano@usuhs.edu
- Phone: (301) 295-3190
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
New therapy dose test for people with prior B-cell cancers
This early-phase study tests different doses of LY4152199 to see if it is safe and effective for people who have already been treated for certain B-cell lymphomas.
-
T-Cell Therapy for Adults with Relapsed B-Cell Non-Hodgkin's Lymphoma
This study is testing a new T-cell therapy to see if it can help adults with relapsed B-cell non-Hodgkin's lymphoma feel better.
-
Treatment for relapsed B-cell lymphoma using CAR-T cells
This study is testing a new CAR-T cell therapy to see if it can help people with relapsed B-cell lymphoma feel better and improve their treatment outcomes.
-
Study of crushed venetoclax tablets dissolved in liquid for pediatric patients
This study tests if crushing venetoclax tablets and mixing them with liquid helps children with blood cancers absorb the medication better and stay safe while taking it.
-
Evaluating CTX112 for B-cell malignancies
This study is testing a new type of CAR T cell therapy called CTX112 to see if it can safely help people with tough-to-treat B-cell cancers.
-
New CAR T-cell therapy for children and young adults with certain blood cancers
This study is testing a new CAR T-cell therapy that uses modified cells from children's and young adults' own blood to see if it can help treat certain tough-to-treat blood cancers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.